Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03253289 · ClinicalTrials.gov registry record · Phase 1
Meclizine for Hepatocellular Carcinoma
A Phase 1 study of Carcinoma, Hepatocellular, sponsored by Tannaz Armaghnay.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 5
- Study locations
NCT03253289 is a Phase 1 study of Carcinoma, Hepatocellular that has completed, run by Tannaz Armaghnay. The registered enrollment target is 13 participants, below the 612-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT03253289, a Phase 1 study of Carcinoma, Hepatocellular, has completed, sponsored by Tannaz Armaghnay.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 5
- Study locations
Study Summary
Meclizine hydrochloride is an antihistamine widely used for treatment of vertigo and motion sickness. In HCC it has been used for anti-emetic effects, but it is used here as a CAR (constitutive androstane receptor) inverse agonist. The hypothesis of this study is that Meclizine, CAR inverse agonist, will have beneficial therapeutic effect in patients with hepatocellular carcinoma who are candidates for surgical resection, ablation, TACE, Y90 or systemic therapy by blocking tumorigenesis and inducing apoptosis. The effects of Meclizine will be analyzed by measuring messenger RNA level of CAR target genes CYP2B6, c-Myc and FoxM1, the downstream effectors of CAR, by real time quantitative PCR.
Conditions Studied
Interventions
- DRUG Meclizine Oral Tablet
Study Locations (5)
Texas
- Baylor College of Medicine -McNair Campus - Houston
- Baylor College of Medicine - Houston
- Baylor St. Luke's Medical Center - Houston
- Ben Taub General Hospital - Houston
- Harris Health System- Smith Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-10-13 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03253289
The ClinicalTrials.gov registry entry for NCT03253289 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 612-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (98% lower). The listed sponsor is Tannaz Armaghnay, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 1 intervention - of which Meclizine Oral Tablet is the first listed.
NCT03253289 reports 5 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03253289 about?
NCT03253289 is a clinical study titled "Meclizine for Hepatocellular Carcinoma". Meclizine hydrochloride is an antihistamine widely used for treatment of vertigo and motion sickness. In HCC it has been used for anti-emetic effects, but it is used here as a CAR (constitutive androstane receptor) inverse agonist. The hypothesis of this study is that Meclizine, CAR inverse agonist...
What is the current status of trial NCT03253289?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-10-13. Estimated completion is 2023-03-28.
What conditions does trial NCT03253289 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT03253289?
The interventions under investigation include: Meclizine Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03253289?
This trial is sponsored by Tannaz Armaghnay, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03253289 being conducted?
This trial has 5 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
COMPLETED · Phase 1
-
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
COMPLETED · Phase 1
-
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.